Comparison of histological tumour response in patients with hepatocellular carcinoma after transarterial chemoembolization, stereotactic body radiation, or combined therapy
- Weitere Titel
-
Vergleich des histologischen Tumoransprechens bei Patienten mit hepatozellulärem Karzinom nach TACE, SBRT oder Kombinationstherapie
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Technische Universität München, Dissertation, 2022
- Schlagwort
-
Patients
Therapeutics
Liver--Cancer
Radiation
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der TU München
- (wann)
-
2022
- Urheber
-
Bauer, Ulrike Anna
- Beteiligte Personen und Organisationen
- URN
-
urn:nbn:de:bvb:91-diss-20220219-1613531-1-3
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bauer, Ulrike Anna
- Ehmer, Ursula
- Mogler, Carolin
- Universitätsbibliothek der TU München
Entstanden
- 2022
Ähnliche Objekte (12)
Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma
Subclinical hepatocellular carcinoma
Progress in hepatocellular carcinoma treatment
Targeting FUBP1 in Hepatocellular Carcinoma
Targeting FUBP1 in hepatocellular carcinoma
Pathogenesis of human hepatocellular carcinoma
Multidisciplinary treatment of hepatocellular carcinoma
Stereotactic microwave ablation of hepatocellular carcinoma: the impact of tumor size and minimal ablative margin on therapeutic success
T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy
Immunophenotyping of the hepatocellular carcinoma patients
Update on glycosphingolipids abundance in hepatocellular carcinoma
Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma
Subclinical hepatocellular carcinoma
Progress in hepatocellular carcinoma treatment
Targeting FUBP1 in Hepatocellular Carcinoma
Targeting FUBP1 in hepatocellular carcinoma
Pathogenesis of human hepatocellular carcinoma
Multidisciplinary treatment of hepatocellular carcinoma
Stereotactic microwave ablation of hepatocellular carcinoma: the impact of tumor size and minimal ablative margin on therapeutic success
T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy
Immunophenotyping of the hepatocellular carcinoma patients
Update on glycosphingolipids abundance in hepatocellular carcinoma
Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma
Subclinical hepatocellular carcinoma
Progress in hepatocellular carcinoma treatment
Targeting FUBP1 in Hepatocellular Carcinoma
Targeting FUBP1 in hepatocellular carcinoma
Pathogenesis of human hepatocellular carcinoma
Multidisciplinary treatment of hepatocellular carcinoma
Stereotactic microwave ablation of hepatocellular carcinoma: the impact of tumor size and minimal ablative margin on therapeutic success
T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy
Immunophenotyping of the hepatocellular carcinoma patients